Connect with the future of healthcare
Dipneo is a spin-off from Eurecat created to develop an autonomous resuscitator device capable of providing controlled and optimized ventilation to unconscious patients or those unable to breathe independently. It serves as support for both professional and non-professional individuals providing first aid for resuscitation in emergency situations involving cardiopulmonary arrest.
Premarket/clinical phase
2.400.000€
2027-2029
Medical devices
10.7%
1.000€
Share this project on your website.
Copy and paste the following code into your content.
Dipneo is a Deep Tech-based startup created in early 2023 dedicated to creating portable and autonomous resuscitation medical devices that enable the digitalization of emergency medical care, ultimately aiming to save lives.
The business project was launched in February 2023 by entrepreneurs Xavier Castells (CEO), Julio Díaz (CTO), and Ferrán Soldevila (investor and advisor), with Mobile World Capital and the Eurecat Foundation as investors. The project was initially developed at the Eurecat Foundation in collaboration with Mobile World Capital’s acceleration program, The Collider, which allowed the formation of an entrepreneurial team with extensive technological and business experience, supported by top-tier advisors.
Cardiopulmonary Resuscitation (CPR) maneuvers are a set of techniques designed to maintain blood flow and oxygenation in the body of a person who has suffered cardiac arrest. Having good tools to provide a response to cardiac arrest is crucial to survival rates; every minute counts in this type of medical emergency, as in the event of a cardiopulmonary arrest, the survival rate decreases by 10% for every minute that the patient does not receive care. Additionally, the annual incidence of cardiopulmonary arrest in Europe is 67 to 170 per 100,000 inhabitants, and the average survival rates are only about 10%.
A critical aspect of managing cardiac arrest is ensuring adequate oxygenation and ventilation. In this regard, a medical ventilation device plays a crucial role in providing respiratory assistance to patients with cardiopulmonary arrest. Dipneo has developed a first prototype of an autonomous ventilation system that has been successfully validated by resuscitation and emergency medical professionals using an advanced simulator mannequin at the Hospital de Sant Pau. This prototype forms the technological foundation of the Air2Life project. This base technology, to be developed in this project, holds an international patent owned by Eurecat and exclusively licensed to Dipneo (WO 2022023595 A1).
The main objective of the project is to develop an autonomous resuscitator device capable of providing controlled and optimized ventilation to unconscious patients or those unable to breathe independently. It serves as support for both professional and non-professional individuals performing first aid for resuscitation in emergency situations involving cardiopulmonary arrest. Advanced and cutting-edge technologies will be used in the design and development of the device: such as technology for the tricuspid collapse of the resuscitator, automation systems, communication systems for teleassistance, and augmented reality technologies.
As a result of the project, we expect to obtain a new, lightweight, and compact device that can be integrated into the emergency kits used by emergency and rescue personnel. Air2Life will be an IoT device capable of bidirectional communication with medical centers and a cloud platform.
The device will include hardware and a mobile device for its control. Our device will provide a better user experience, adequate ventilation in volume and cadence, monitoring, and control of the pressure of the flow to the patient, making ventilation safer and synchronized with cardiac massage. Additionally, this project will enable the collection and storage of important data derived from the device’s use to be utilized as functional indicators, along with an infrastructure that supports it and a digital platform that allows monitoring and control of these indicators and devices, as well as regulating communication with the mobile device.
In cases of cardiorespiratory arrest, Cardiopulmonary Resuscitation (CPR) maneuvers are vital. Although automatic defibrillators are becoming increasingly common in public places such as subways, schools, and hospitals, they address only part of the problem. The Dipneo device is the perfect complement to these defibrillators, ensuring the necessary oxygenation and blood flow until professional medical assistance arrives, filling an important gap in initial emergency care.
Dipneo aims to become the ideal complement to automatic defibrillators, which have a rapidly growing market valued at $3.061 billion in 2021, with expectations to reach $15.81 billion by 2031. For instance, in Spain, the number of defibrillators has significantly increased from 10,239 units in 2019 to 33,145 in 2021, demonstrating a robust and expanding market. It is now estimated that there may be more than 50,000 defibrillators, and Dipneo would be a potential product to accompany them.
Dipneo has developed a prototype to validate its technology and meet regulatory requirements, and it has already received several Letters of Intent (LOIs) from distributors for market expansion. Its team, with extensive experience in startups and life sciences, combines skills in business management and technological development, ensuring that Dipneo offers innovative and effective medical solutions for emergencies.
Dipneo faces key challenges such as dependence on external manufacturing and the need for regulatory approvals, which can delay its launch. Convincing institutions and healthcare professionals to adopt a new product can also be a market challenge.
Additionally, managing financial, technological, and intellectual property risks is crucial, especially in a competitive and globalized market where cultural barriers vary widely.
Already have an account? Please login here .